MediciNova, Inc.
$1.47
▲
1.41%
2026-04-21 08:12:00
medicinova.com
NGM: MNOV
Explore MediciNova, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$71.37 M
Current Price
$1.47
52W High / Low
$1.96 / $1.17
Stock P/E
—
Book Value
$0.84
Dividend Yield
—
ROCE
-31.77%
ROE
-25.5%
Face Value
—
EPS
$-0.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
6
Beta
0.61
Debt / Equity
0.51
Current Ratio
8.16
Quick Ratio
8.16
Forward P/E
-3.59
Price / Sales
179.03
Enterprise Value
$42.74 M
EV / EBITDA
-3.22
EV / Revenue
104.34
Rating
None
Target Price
$9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 2. | LeonaBio, Inc. | $9.38 | — | $83.23 M | — | -76.55% | -2.91% | $14.21 / $2.2 | $5.2 |
| 3. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 4. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 5. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 6. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 7. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.15 M | 0.12 M | 0.13 M | 0 M | 0 M | — |
| Operating Profit | -3.09 M | -3.38 M | -3.61 M | -3.2 M | -3.18 M | — |
| Net Profit | -2.8 M | -3.05 M | -3.28 M | -2.86 M | -2.81 M | — |
| EPS in Rs | -0.06 | -0.06 | -0.07 | -0.06 | -0.06 | -0.06 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.41 M | 0 M | 1 M | 0 M |
| Operating Profit | -13.28 M | -12.68 M | -9.9 M | -14.63 M |
| Net Profit | -12 M | -11.05 M | -8.57 M | -14.07 M |
| EPS in Rs | -0.24 | -0.22 | -0.17 | -0.29 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 45.6 M | 55.88 M | 66.27 M | 74.15 M |
| Total Liabilities | 4.02 M | 3.37 M | 3.89 M | 3.91 M |
| Equity | 41.59 M | 52.5 M | 62.38 M | 70.24 M |
| Current Assets | 30.99 M | 41.07 M | 51.17 M | 58.99 M |
| Current Liabilities | 3.8 M | 2.96 M | 3.28 M | 3.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.81 M | -10.64 M | -7.43 M | -12.91 M |
| Investing CF | -0 M | -0 M | 39.91 M | -40.01 M |
| Financing CF | 0.24 M | 0 M | 0 M | 0.01 M |
| Free CF | -9.81 M | -10.64 M | -7.45 M | -12.92 M |
| Capex | -0 M | -0 M | -0.02 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -8.58% | -28.91% | 39.08% | — |
| Profit Margin % | -2928.78% | — | -857.15% | — |
| Operating Margin % | -3242.47% | — | -990.03% | — |
| Gross Margin % | 7.58% | — | — | — |
| EBITDA Margin % | -3237.56% | — | -988% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.